Therapeutic foam

• US 8,703,827 B2
• Filed: 05/12/2006
• Issued: 04/22/2014
• Est. Priority Date: 05/13/2005
• Status: Active Grant

• Current Assignee: Boston Scientific Medical Device Limited (Boston Scientific Corporation)
• Original Assignee: BTG International Limited (Boston Scientific Corporation)
• Inventors: Jenkins, William John
• Primary Examiner(s): Sims, Jason M
• Assistant Examiner(s): Bori, Ibrahim D
• Application Number:
  US11/914,192
• Publication Number:
  US 20090124704A1
• Time in Patent Office: 2,902 Days
• Field of Search: 514/723, 514/769
• US Class Current: 514/723
• CPC Class Codes: A61K 31/08 acyclic, e.g. paraformaldehyde
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/122 Foams; Dry foams edible foams A61K9/0056
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

A foam for the treatment of varicose veins is disclosed, comprising a sclersosant solution, e.g. polidocanol, foamed with a gas mixture which includes greater than 41% of a lipid soluble gas such as xenon. The aim is to provide a foam which may be injected into a varicose vein in large quantities because the gas component is dissipated quickly after the foam has acted on the varicose vein.

Claims

1. A foam comprising a liquid phase and a gas phase wherein the liquid phase comprises at least one sclerosing agent and the gas phase comprises from 41% to 100% of xenon.

2. A foam of claim 1 wherein the gas phase further comprises oxygen, carbon dioxide or a mixture of oxygen and carbon dioxide.

3. A foam of claim 1 wherein the sclerosing agent is polidocanol.

4. A method of treating varicose veins comprising injecting into a vein in need thereof a foam of claim 1.

5. A method of claim 4 wherein a greater saphenous vein is treated in one injection.

6. A method of claim 4 wherein between 15 ml and 50 ml of the foam is injected.